Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin JR, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M.

Clin Cancer Res. 2018 Apr 17. pii: clincanres.3004.2017. doi: 10.1158/1078-0432.CCR-17-3004. [Epub ahead of print]

PMID:
29666304
2.

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.

Li L, Xiao S, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Zhang X, Chang Y, Nan F, Yan J, Li Z, Shi M, Young KH, Zhang M.

Oncotarget. 2018 Jan 2;9(22):16213-16219. doi: 10.18632/oncotarget.23806. eCollection 2018 Mar 23.

3.

Targeting the Leukemia Antigen PR1 with Immunotherapy for the treatment of Multiple Myeloma.

Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia RS, Sergeeva A, Yi S, Young KH, Philips AV, Herrmann AC, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ.

Clin Cancer Res. 2018 Apr 16. pii: clincanres.2626.2017. doi: 10.1158/1078-0432.CCR-17-2626. [Epub ahead of print]

PMID:
29661776
4.

miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.

Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M, Zhou Z, Li L, Zeng Z, Young KH, Zhang M, Li Y.

Oncogene. 2018 Mar 15. doi: 10.1038/s41388-018-0178-3. [Epub ahead of print]

PMID:
29540832
5.

Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease.

Quesada AE, Young KH, Medeiros LJ, Thakral B.

Pathology. 2018 Apr;50(3):351-352. doi: 10.1016/j.pathol.2017.09.017. Epub 2018 Mar 2. No abstract available.

PMID:
29486963
6.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL Jr, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF.

Clin Cancer Res. 2018 Feb 23. doi: 10.1158/1078-0432.CCR-17-3561. [Epub ahead of print]

PMID:
29476021
7.

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.

García-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Böttcher S, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA.

J Pathol. 2018 May;245(1):61-73. doi: 10.1002/path.5060. Epub 2018 Mar 30.

PMID:
29464716
8.

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2018 Feb 15;13(2):e0192988. doi: 10.1371/journal.pone.0192988. eCollection 2018.

9.

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV.

Oncotarget. 2017 Aug 21;9(1):346-360. doi: 10.18632/oncotarget.20378. eCollection 2018 Jan 2.

10.

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.

Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, Zhang L, Wang X, Wu J, Li Z, Nan F, Tian L, Li W, Young KH.

J Hematol Oncol. 2018 Jan 31;11(1):15. doi: 10.1186/s13045-018-0559-7.

11.

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Xu-Monette ZY, Zhang M, Li J, Young KH.

Front Immunol. 2017 Dec 4;8:1597. doi: 10.3389/fimmu.2017.01597. eCollection 2017. Review.

12.

Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma.

Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, Lofts J, Amin MB, Ming Chai S, Morine A, Di Napoli A, Dogan A, Parkash V, Bhagat G, Tritz D, Quesada AE, Pina-Oviedo S, Hu Q, Garcia-Gomez FJ, Jose Borrero J, Horna P, Thakral B, Narbaitz M, Hughes RC 3rd, Yang LJ, Fromm JR, Wu D, Zhang D, Sohani AR, Hunt J, Vadlamani IU, Morgan EA, Ferry JA, Szigeti R, C Tardio J, Granados R, Dertinger S, Offner FA, Pircher A, Hosry J, Young KH, Miranda RN.

Am J Surg Pathol. 2018 Mar;42(3):293-305. doi: 10.1097/PAS.0000000000000985.

PMID:
29194092
13.

Diffuse large B-cell lymphoma.

Li S, Young KH, Medeiros LJ.

Pathology. 2018 Jan;50(1):74-87. doi: 10.1016/j.pathol.2017.09.006. Epub 2017 Nov 20. Review.

PMID:
29167021
14.

STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2017 Nov 14;12(11):e0187532. doi: 10.1371/journal.pone.0187532. eCollection 2017. Erratum in: PLoS One. 2018 Feb 15;13(2):e0192988.

15.

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Xu-Monette ZY, Zhou J, Young KH.

Blood. 2018 Jan 4;131(1):68-83. doi: 10.1182/blood-2017-07-740993. Epub 2017 Nov 8. Review.

PMID:
29118007
16.

CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.

Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, Yin CC, Young KH, Patel KP, Miranda RN, Goswami M, Wang M, Jorgensen JL, Medeiros LJ, Wang SA.

Mod Pathol. 2018 Feb;31(2):327-336. doi: 10.1038/modpathol.2017.135. Epub 2017 Oct 6.

PMID:
28984300
17.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.

Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345. Epub 2017 Sep 26.

PMID:
28949959
18.

Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.

Li X, Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, Fowler N, Miranda RN, Zhang M, Ferry JA, Medeiros LJ, Harris NL, Young KH.

Am J Surg Pathol. 2017 Oct;41(10):1309-1321. doi: 10.1097/PAS.0000000000000923.

PMID:
28817403
19.

Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.

Wu H, Medeiros LJ, Young KH.

Blood Rev. 2018 Jan;32(1):8-28. doi: 10.1016/j.blre.2017.08.004. Epub 2017 Aug 8. Review.

PMID:
28802908
20.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222. Epub 2017 Jul 12.

PMID:
28745330
21.

Targeting nucleolin for better survival in diffuse large B-cell lymphoma.

Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, Singh RK, Berkova Z, Wise JF, Braun FK, Wang X, Patel K, Xu-Monette ZY, Courty J, Young KH, Sehgal L, Samaniego F.

Leukemia. 2018 Mar;32(3):663-674. doi: 10.1038/leu.2017.215. Epub 2017 Jul 10.

PMID:
28690315
22.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.

Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009. Epub 2017 Jun 13.

PMID:
28627414
23.

The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.

Li L, Duan W, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Zhang X, Chang Y, Nan F, Yan J, Li Z, Young KH, Zhang M.

Br J Haematol. 2017 Sep;178(5):772-780. doi: 10.1111/bjh.14763. Epub 2017 Jun 9.

PMID:
28597542
24.

Inhibition of the Continuum of Radiation-Induced Normal Tissue Injury by a Redox-Active Mn Porphyrin.

Birer SR, Lee CT, Choudhury KR, Young KH, Spasojevic I, Batinic-Haberle I, Crapo JD, Dewhirst MW, Ashcraft KA.

Radiat Res. 2017 Jul;188(1):94-104. doi: 10.1667/RR14757.1.S1. Epub 2017 May 18.

PMID:
28517962
25.

Checkpoint inhibitors in hematological malignancies.

Ok CY, Young KH.

J Hematol Oncol. 2017 May 8;10(1):103. doi: 10.1186/s13045-017-0474-3. Review.

26.

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.

Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC.

Leuk Lymphoma. 2017 Dec;58(12):2833-2844. doi: 10.1080/10428194.2017.1312381. Epub 2017 May 9.

PMID:
28482717
27.

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ.

Leukemia. 2017 Jul;31(7):1633-1637. doi: 10.1038/leu.2017.103. Epub 2017 Mar 27. No abstract available.

PMID:
28344319
28.

NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH.

Mod Pathol. 2017 Jun;30(6):854-876. doi: 10.1038/modpathol.2017.5. Epub 2017 Mar 10.

PMID:
28281555
29.

Immunophenotypic Shifts in Primary Cutaneous γδ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.

Agbay RL, Torres-Cabala CA, Patel KP, Merril ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff M, Li S, Medeiros LJ, Miranda RN.

Am J Surg Pathol. 2017 Apr;41(4):431-445. doi: 10.1097/PAS.0000000000000786.

PMID:
28248813
30.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M.

Blood. 2017 May 4;129(18):2584-2587. doi: 10.1182/blood-2016-11-749903. Epub 2017 Feb 28. No abstract available.

PMID:
28246192
31.

Targeting the programmed death-1 pathway in lymphoid neoplasms.

Ok CY, Young KH.

Cancer Treat Rev. 2017 Mar;54:99-109. doi: 10.1016/j.ctrv.2017.01.009. Epub 2017 Feb 11. Review.

32.

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH.

Blood. 2017 Mar 23;129(12):1658-1668. doi: 10.1182/blood-2016-11-748855. Epub 2017 Jan 18.

33.

Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Yabe M, Medeiros LJ, Daneshbod Y, Davanlou M, Bueso-Ramos CE, Moran EJ, Young KH, Miranda RN.

Ann Diagn Pathol. 2017 Feb;26:16-22. doi: 10.1016/j.anndiagpath.2016.10.005. Epub 2016 Oct 18.

34.

Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

Sun R, Wang J, Young KH.

Crit Rev Oncog. 2017;22(5-6):527-557. doi: 10.1615/CritRevOncog.2017020816.

PMID:
29604930
35.

RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.

Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.

Aging (Albany NY). 2016 Dec 8;8(12):3321-3340. doi: 10.18632/aging.101121.

36.

Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.

McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR Jr, Gough MJ, Raber J.

Oncotarget. 2017 Feb 7;8(6):9155-9173. doi: 10.18632/oncotarget.13551.

37.

Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas.

Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH, Curry JL, Nagarajan P, Ivan D, Prieto VG, Medeiros LJ, Duvic M, Torres-Cabala CA.

Am J Surg Pathol. 2017 Feb;41(2):204-215. doi: 10.1097/PAS.0000000000000768.

PMID:
27879514
38.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

39.

Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.

Hu Z, Medeiros LJ, Chen Z, Chen W, Li S, Konoplev SN, Lu X, Pham LV, Young KH, Wang W, Hu S.

Am J Surg Pathol. 2017 Feb;41(2):216-224. doi: 10.1097/PAS.0000000000000758. Erratum in: Am J Surg Pathol. 2017 May;41(5):723.

PMID:
27776009
40.

NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Yu L, Li L, Medeiros LJ, Young KH.

Blood Rev. 2017 Mar;31(2):77-92. doi: 10.1016/j.blre.2016.10.001. Epub 2016 Oct 13. Review.

41.

Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis.

Yabe M, Medeiros LJ, Wang SA, Tang G, Bueso-Ramos CE, Jorgensen JL, Bhagat G, Chen W, Li S, Young KH, Miranda RN.

Am J Surg Pathol. 2017 Jan;41(1):82-93.

PMID:
27755009
42.

An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.

Mai Y, Yu JJ, Bartholdy B, Xu-Monette ZY, Knapp EE, Yuan F, Chen H, Ding BB, Yao Z, Das B, Zou Y, Young KH, Parekh S, Ye BH.

Blood. 2016 Dec 15;128(24):2797-2807. Epub 2016 Oct 13.

43.

Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.

Pham LV, Bryant JL, Mendez R, Chen J, Tamayo AT, Xu-Monette ZY, Young KH, Manyam GC, Yang D, Medeiros LJ, Ford RJ.

Oncotarget. 2016 Dec 6;7(49):80599-80611. doi: 10.18632/oncotarget.12413.

44.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH.

Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243. Epub 2016 Aug 29.

45.

Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists.

Tang Z, Medeiros LJ, Yin CC, Wang W, Lu X, Young KH, Khoury JD, Tang G.

Mol Cytogenet. 2016 Aug 8;9:62. doi: 10.1186/s13039-016-0275-3. eCollection 2016.

46.

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma.

Friedman D, Baird JR, Young KH, Cottam B, Crittenden MR, Friedman S, Gough MJ, Newell P.

Hepatol Res. 2017 Jun;47(7):702-714. doi: 10.1111/hepr.12789. Epub 2016 Sep 22.

PMID:
27501850
47.

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.

Zhang L, Jia S, Ma Y, Li L, Li X, Wang X, Fu X, Ma W, Qin Y, Li W, Wu J, Sun Z, Zhang X, Nan F, Chang Y, Li Z, Zhang D, Wang G, Yan J, Su L, Wang J, Xue H, Young KH, Zhang M.

Oncotarget. 2016 Aug 23;7(34):55721-55731. doi: 10.18632/oncotarget.10124.

48.

Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Sun R, Medeiros LJ, Young KH.

Mod Pathol. 2016 Oct;29(10):1118-42. doi: 10.1038/modpathol.2016.92. Epub 2016 Aug 1. Review.

49.

Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades.

Castro KG, Marks SM, Chen MP, Hill AN, Becerra JE, Miramontes R, Winston CA, Navin TR, Pratt RH, Young KH, LoBue PA.

Int J Tuberc Lung Dis. 2016 Jul;20(7):926-33. doi: 10.5588/ijtld.15.1001.

50.

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.

Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR.

PLoS One. 2016 Jun 9;11(6):e0157164. doi: 10.1371/journal.pone.0157164. eCollection 2016.

Supplemental Content

Loading ...
Support Center